In this paper, a new robust terminal synergetic control scheme is proposed to regulate blood glucose level in diabetic patients (type I diabetes), based on recently developed synergetic control and a terminal attractor technique. The technique presented has the advantage of using a continuous control law. Moreover, the proposed control scheme, besides being chattering free, has the characteristics of finite time convergence. Lyapunov synthesis is adopted to ensure controlled system stability. Simulation results of terminal synergetic control are compared to classic synergetic and second-order sliding mode control (SMC) performance, demonstrating that the proposed control method allows for rapidly achieving normoglycemia in type I diabetes patients.
Introduction
Diabetes, a chronic metabolic disease (type I diabetes), usually starting in childhood or early adulthood, is characterized by the production of little or no insulin, causing an abnormal rise in blood glucose level which when untreated can cause severe complications (hypoglycemic coma, damage blood vessels and nerves). In type I diabetes, also called "insulin-dependent diabetes," the pancreas secretes little or no insulin which keeps blood sugar at a consistently high level causing severe health problems with no apparent symptoms for years. Gradually, as the disease progresses, the following signs appear suddenly usually when most (80 to 90%) of the cells in the pancreas have disappeared:
(1) increased thirst and hunger; (2) frequent urination; (3) abnormal fatigue; and (4) dry and itchy skin.
It is, therefore, imperative to keep blood sugar levels within the normal range to prevent further complications. Beyond insulin injection, maintaining a reasonable weight, a balanced diet, and practicing a regular physical activity are essential components of the treatment.
Treatment is based on one to five daily regular injection of insulin, with an adaptation to the diet. Patients can reduce their own risk of complications, including self-monitoring of their blood sugar. Thus, it is necessary to check blood sugar level several times a day and inject via a special pen the right dose of insulin. This constant monitoring becomes rapidly burdensome spoiling daily life quality in type I diabetes patients. An adequate solution seems to be the use of an automatic external pump as an artificial pancreas. This pump has a digital control, which completely replaces the pancreas for insulin-dependent diabetes. The human body is very sensitive to glucose concentration excursion in the blood compared to the basal level and a small disturbance for a long period can cause many complications; that is why a robust and fast controller is needed and this makes up the issue addressed in this paper.
It is evident that physical characteristics vary from one person to another and different patients have different responses to the same treatment, and changes in some of the parameters may significantly affect the performance of a glucose regulation. Thus, it is essential for patients that the controller used in designing the closed-loop system is robust to any kind of disturbances (meals) and uncertainties in parameters (patient parameters).
Several control schemes have been previously proposed for designing tracking controllers for insulin delivery, such as proportionalderivative controller [1] and H 1 controller [2] both requiring a linearized model for the design which obviously hinders robustness. Predictive control [3] is yet another approach proposed in which the model is used to predict and to minimize the tracking error, therefore, the insulin infusion rate is determined from the model of the process; resolution was repeated at every 10-15 min; with this type of control, there may be a problem of hypoglycemia. The latter is an excessive drop in blood sugar, less than 0.60 g/l, which is dangerous and can lead to sudden death. Moreover, the linearization of the input-output model must be based on precise mathematics, while physical systems undergo parametric variations and are subject to external disturbances. These concerns have let to resort to proven robust techniques such as sliding mode control (SMC) characterized by their invariance with respect to system dynamics when is sliding regime.
Sliding mode control has been widely used in robust control approaches in many nonlinear applications [4] [5] [6] amidst control of the glucose-insulin regulatory system [7, 8] . Well known for its robustness, SMC suffers from its main disadvantage, chattering phenomenon, which may excite neglected dynamics and induce instability and may cause severe damage to actuators through highfrequency control effort [9] . Aiming to overcome this problem, several solutions have been proposed among which is Ref. [10] as well as the application of high-order sliding mode [11] . The latter approach has been proposed in regulating the blood glucose concentration at the basal level [8] .
All these approaches alleviate chattering to different degrees at expenses of robustness and often added complexity; similar to SMC, the synergetic approach, a robust control technique based on analytical design of aggregated regulators [12] , seems to circumvent chattering as a whole by the use of totally continuous control law yet provides for the same level of closed-loop invariance. This technique offers advantages provided by SMC without the chattering problem and will be used in its finite time version to elaborate a robust control to regulate blood glucose level in diabetes type I patients.
Continuously monitoring blood sugar and administrating the correct dose of insulin in an automated manner without intervention from the patient can be realized by an artificial pancreas. The latter consist in a system whose principal organ is an insulin pump enabled by a robust control algorithm to continuously deliver required amount of insulin to diabetes type I patients in real-time as a sane and real pancreas would.
The algorithm used must automatically calculate the insulin dose and adjust in real-time glucose level mimicking the operation of a real and functional pancreas, thus limiting the time spent under hyperglycemia.
In this paper, based on the analytical design of aggregated regulators approach, a new terminal synergetic controller is proposed for the glucose-insulin regulatory system. This controller is developed by combining synergetic control theory and terminal attractor techniques. The proposed controller eliminates the singularity problem associated with terminal finite time approaches [9] . Moreover, it has the advantage of convergence in finite time thus rapidly reducing static errors.
The design of the terminal synergetic control is based on a particular choice of the macrovariable that results in determining a control law to force the system to track a reference signal in a finite time. In this work, we will use Bergman's minimal model [13] to apply and evaluate the proposed controller. Section 2 introduces the model of glucose-insulin system in type I diabetes patient to be considered. Section 3 introduces the design of synergetic controllers. Simulation results will be discussed in Sec. 4 ensued by concluding remarks.
Bergman Minimal Model
Among few models available in the literature, Bergman's minimal model [13] has been used extensively in many research papers. Its simplicity both as a clinical tool and as an approach to understand the composite effects of insulin secretion and insulin sensitivity on glucose tolerance has made it an inevitable station in glucose control in diabetes type I patients. Bergman's minimal model equations represent the physiological factors and are given as follows:
where the Bergman minimal model parameters are described in Table 1 . The term c[G(t) À h] þ acts as an internal regulatory function that formulates the insulin excretion in the body, which does not exist in diabetic patients [13] . A meal is often considered as a disturbance D(t) and must be included to better represent the complete dynamics of the glucose-insulin regulatory system. This disturbance can be modeled by a decaying exponential function of the following form:
Terms of the exponential form c exp(-0.05t) may also be used and represent the Fisher meals standard [14] .
Synthesis of Synergetic Control
Analytical design of aggregated regulator has led to the advent to the synergetic control theory which not only brings about the advantages of the sliding mode control such as robustness and order reduction but enables for chattering elimination through a strictly continuous control law [12] . The synergetic approach is built on the same concept as sliding mode technique in the sense that it forces the system to dynamically evolve according to designer selected dynamics. It differs in that the control is always continuous and uses a macrovariable instead of the switching surface inherent to SMC. The synergetic controllers used in this paper are now developed after a brief recall of the synergetic control basics.
3.1 Synergetic Control Overview. Consider the nonlinear dynamic single input single output system of dimension n which is described by the following nonlinear differential equation:
where x is the system state vector and u is the control vector. Synthesis of synergetic control law begins with the definition of a macrovariable by the designer to achieve desired specifications and is described as follows:
As in SMC approach, the objective of the synergetic control is to force the system to evolve on a designer chosen manifold
The macrovariable can be a linear combination of state variables and is forced to evolve in a desired manner by means of a constraint selected by the designer imposing transient dynamics for instance as indicated by the following equation:
where T is a control parameter that indicates the system convergence speed toward the specified domain. Taking into account the chain of differentiation which is given by Rate at which insulin is being used up in plasma h mg/dl Threshold value of glucose above which the pancreatic b-cells release insulin c l U/ml min À2 (mg/dl)
À1
Rate of the pancreas b-cells' release of insulin after the glucose injection with glucose concentration above the threshold u(t) mU/min Exogenous insulin
Substituting Eqs. (3) and (4) into Eq. (6) gives
Resolution of (8) for u leads to the synergetic control law u ¼ gðx; wðx; tÞ; T; tÞ
It is clear from Eq. (9) that the control law is continuous and that it depends not only on the system state variables but also on control designer selected macrovariable and time constant T. By appropriate choice of macrovariables, the designer can obtain the following interesting features for the final system [12] :
(1) overall stability; (2) insensitivity to system parameters variations; and (3) noise suppression.
In the ensuing section, the synergetic approach is applied to regulate blood glucose in type I diabetes patients relying on Bergman's simplified model.
Synergetic Controller for Blood Glucose Regulation.
The system introduced in Eq. (1) can be rewritten in state-space form as follows:
where x 1 , x 2 , and x 3 represent blood plasma glucose concentration (mg/dl), the insulin's effect on the net glucose disappearance (1/min), and the insulin concentration in plasma (lU/ml), respectively. Let the expected glucose concentration reference in the diabetic patient's blood be G b , then the tracking error can be defined as
The first step is to define the relative degree of the system; using Eq. (10), the control function appears in the equation after the third differentiation, i.e., 
where
Let the selected synergetic macrovariable be given as follows:
The designer can select the characteristics of this macrovariable according to the control specifications. In this case, c 1 and c 0 are chosen so as to impose slightly damped oscillatory error dynamics with little or no overshoot. The same process can be repeated, defining as many macrovariables as control channels. The elaborated synergetic controller will force the system to operate on manifold
Furthermore, desired dynamic evolution of the macrovariable can be chosen as
Directly substituting Eqs. (13) and (14) into Eq. (10) and rearranging, the control law u is obtained as
with p 3 6 ¼ 0, x 1 6 ¼ 0, and p 3 x 1 2 ½1:2 Â 10 À4 ; 3 Â 10 À2 , and c 1 and c 0 are real-valued constants. Asymptotic stability is obtained and can be asserted using the following Lyapunov function candidate:
which after differentiation leading to
Substituting Eq. (15) into Eq. (18) leads to
The synergetic control elaborated guarantees only an asymptotic convergence; to have a finite time convergence, it is necessary to modify the macrovariable that is undertaken in Sec. 3.3.
Terminal Synergetic
Controller for Blood Glucose Regulation. The so-called terminal approach [5, 9] enables for obtaining finite convergence granted by the concept of terminal attraction. The proposed controller will be designed such that the system states would be driven onto the specified manifold within a finite time according to a modified constraint
where p and q are positive odd reals satisfying condition 1 < p/ q < 2. Keeping the same choice of the macrovariable as in Eq. (13)
Using Eqs. (20) and (21) provides
Equations (19) and (23) lead to the following control law:
Since p 3 6 ¼ 0, x 1 6 ¼ 0, and p 3 x 1 2 ½1:2 Â 10 À4 ; 3 Â 10 À2 , c 1 and c 0 are real-valued constants. THEOREM 1. Consider a class of nonlinear systems (10), the system states will converge in finite time with the rate of convergence depending on the parameters p and q with the control law (23) 
. LEMMA 1 [9] . Let a continuous, positive-definite function satisfy the following inequality:
where a > 0; 0 < g < 1 are constants. Then, for any given t 0 ; VðtÞ satisfies the following inequality:
And VðtÞ 0; 8t ! t 1
With t 1 given by
From Lemma 1, it can be obtained that the synergetic manifold can converge to zero at the finite time t 1 given by
Simulation Results
Simulation tests are run to compare synergetic and terminal synergetic control performances under different scenarios to that obtained through the second-order sliding mode control [15] . To test the robustness of the control algorithms, their insensitivity with respect to disturbances and parameter uncertainties, simulations are carried out for postprandial states and for three different diabetic patients (Table 2 ) [8] . The tested scenarios consist in the control application upon (1) a hyperglycemic event starting at 300 mg/dl; (2) three meal ingestion events. The reference plasma blood glucose level is considered as 80 mg/dl.
Experiments 1: Simulations represent a postprandial event of a diabetic patient, starting at a blood glucose level of 300 mg/dl, where synergetic and terminal synergetic control are used to control the glucose concentration on three different patients. Figures 1 and 2 show the glucose concentration level of the patients using the synergetic control and terminal synergetic control, respectively; it is stabilized in an acceptable time (100 min). There is no hypoglycemia occurrence, consequently, stability is guaranteed despite uncertainties in parameters associated with different patients. In Figs. 3 and 4 , insulin concentration dose prescribed by both controllers to achieve normoglycemia is efficient despite different doses used for each patient. Nevertheless in Fig. 5 comparing the two responses, one can clearly observe that terminal synergetic control has a faster response over that of synergetic control.
The second-order sliding mode blood glucose control simulation results have also been included in Fig. 5 to better assess the proposed controller. All three controllers perform adequately Experiments 2: Another approach to control glucose concentration level by closed-loop insulin infusion, in this simulation experiment, patient 3 is subjected to three meals divided over breakfast (8 am) , lunch (2 pm), and dinner (8 pm) with 60 g of carbohydrate (CHO) taken orally for 15 min each.
Figures 6 and 7 illustrate a day (with three meals) glucoseinsulin profile of a patient subjected to terminal synergetic control. The glucose-insulin profile reveals that even when a patient is subjected to 60 g meal (CHO), the blood glucose level remains within acceptable regulation values of 80 þ 30 mg/dl by controlled infusion rate of insulin within limits of 4 mU/min over the basal dose. Thus, hyperglycemia and hypoglycemia events in blood glucose level do not appear which is within an acceptable limit and the insulin dose is well controlled between 0 and 36 mU/min.
Conclusion
This paper develops a terminal synergetic control for a blood glucose regulation in diabetes patients. Then, based on synergetic control theory and the terminal attractor technique, a terminal synergetic controller is developed and simulation results compared to both synergetic and second-order sliding mode controllers. Terminal approach guarantees finite time convergence, while keeping up system robustness tested by the intake of meals as external disturbances and different patient models which can be considered as parametric uncertainties. Furthermore, stability and finite time convergence of the proposed controller has been proven. Finally, simulation indicates clearly that terminal synergetic control can deliver faster blood glucose regulation with no hypoglycemia occurrences than synergetic or sliding mode controls. Real-time testing of the proposed controller should be undertaken in future work to confirm its efficacy in enhancing life quality and conferring significant autonomy in type I diabetes patients. 
